Clinical trial

Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis.

Name
PI_ PAL_V3_ 8
Description
To evaluate pain relief from corticosteroid injection with and without anesthetic as well as with variable volume of anesthetic. Pain relief will be measured using the VAS pain score at the time of the injection as well as several time points following the injection to capture pain relief longevity. The investigators intend to evaluate how well the patients tolerate corticosteroid mixtures without anesthetic as well as with different volumes of anesthetic. Primary measure will be the time from procedure when postoperative status is considered success (as measured by global perceived improvement score).
Trial arms
Trial start
2023-06-01
Estimated PCD
2024-06-01
Trial end
2024-06-01
Status
Recruiting
Phase
Early phase I
Treatment
Kenalog with bupivacaine Injection
Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.
Arms:
Kenalog with 0.25% bupivacaine, Kenalog with 0ml bupivacaine, Kenalog with 4ml bupivacaine
Other names:
Knee Injection, Corticosteroid Injection, Kenalog, Bupivacaine
Size
75
Primary endpoint
Injection for Knee Pain
Prior to procedure (in office)
Injection for Knee Pain
Immediate post procedure (in office)
Injection for Knee Pain
2 minutes post procedure (in office)
Injection for Knee Pain
Day 1 post procedure (phone interview)
Injection for Knee Pain
Day 14 post procedure (through EDC)
Injection for Knee Pain
Day 42 post procedure (in office)
Injection for Knee Pain
Day 84 post procedure (through EDC)
Eligibility criteria
Inclusion Criteria: 1. Patients must be 18 years of age and be able to consent for themselves. 2. OA grade Kellgren Lawrence Stage II or III. 3. Diagnosis of primary osteoarthritis. Exclusion Criteria: 1. Patients with other forms of arthritis such as inflammatory arthritis. 2. History of narcotic use for the past 6 months. 3. Kellgren Lawrence arthritis grade 1 or 4. 4. Pregnant women and prisoners.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': "At screening/baseline, informed consent will be obtained, demographics and medical history will be collected, patient x-ray will be reviewed/KL grade confirmed, narcotic use in last 6 months will be screened using E-FORCSE (Florida Prescription Drug Monitoring Program) database, inclusion and exclusion criteria will be assessed, and patient will be randomized into one of the study groups. We will only include patients who are receiving unilateral knee injections. Further, patient's baseline information on VAS Pain and current medication (analgesic or NSAID) will be collected. VAS Pain will be also collected immediately after the intervention and 2 minutes after the intervention, in addition to global perceived improvement score and AEs.\n\nThe intervention in this study is intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic (0ml, 2ml or 4 ml of 0.25% bupivacaine).", 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'maskingDescription': 'The PI standard of care is to offer patients who complain of knee pain a corticosteroids injection regardless of patient participation in a study. A consent will be obtained prior the injection by a trained/qualified team member. Subjects will be randomly allocated to groups by concealed allocation. Randomization sequence between three groups will be created using Excel and will be further stratified by sex within each block, to ensure even distribution. A set of numbered envelopes will be created, with each having one unique group assigned. A staff member will assign an envelope with group assignment upon consent and record envelope number ID. The ARNP will open an envelope, administer injection based on the group assigned. The ARNP will prepare the medication to maintain the double blinded aspect of the study. The ARNP is trained and experienced with injections and has giving injections for several years. She will not be involved in the evaluations of the patient pre/post injection.', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 75, 'type': 'ESTIMATED'}}
Updated at
2023-06-15

1 organization

1 product

1 indication